BioSpace News Archive

Headquartered in London and with operations in Europe and North America, Virtual Science creates cutting-edge software as a service (SaaS) in the life-science and healthcare sectors.

Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Dicyclomine Hydrochloride Tablets, USP 20 mg.

Catalyst OrthoScience Inc. has announced publication of a new study in the Journal of Shoulder and Elbow Surgery that shows positive clinical outcomes using the Catalyst™ CSR total shoulder system, compared to standard stemmed TSAs.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 2b clinical trial evaluating MK-0616.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced full results from the Phase 3 STELLAR trial, which evaluated sotatercept, Merck’s novel investigational activin signaling inhibitor biologic, in combination with stable background therapy for the treatment of adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1).

Hamamatsu announced a multi-year distribution agreement with Siemens Healthineers.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its fourth quarter and year end 2022 update and financial results on Thursday, March 9 at 8:30 a.m. ET.

Nurix Therapeutics, Inc. announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will provide a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on Tuesday, March 14 at 10:40 a.m. ET.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the fourth quarter and full year ending December 31, 2022.

Avid Bioservices, Inc. today announced that it will report financial results for the third quarter of fiscal year 2023 on March 13, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).